Finance

Lists
Q3 2026 earnings • released • EPS beat +5.56% • Revenue beat +0.14%
See results
COLL:NASDAQ
Collegium Pharmaceutical Inc
$24.21
-3.78%
(-0.95) 1D
$24.29
+0.33% (+0.080)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COLL...
Open
$24.06
High
$24.80
Low
$23.71
Mkt. cap
788.17M
Avg. vol.
701.46K
Volume
775.58K
P/E ratio
19.72
52-wk high
$50.79
52-wk low
$21.43
EPS
$1.23
Beta
0.75
Shares outstanding
32.56M
No. of employees
423
Open
$24.06
High
$24.80
Low
$23.71
Mkt. cap
788.17M
Avg. vol.
701.46K
Volume
775.58K
P/E ratio
19.72
52-wk high
$50.79
52-wk low
$21.43
EPS
$1.23
Beta
0.75
Shares outstanding
32.56M
No. of employees
423
News stories
From web sources and news partners
About Collegium Pharmaceutical Inc
CEO-
Employees423
Founded2002
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitecollegiumpharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to COLL in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for COLL in the last 3 months.
Highest
Current $24.21
$60.00 (+147.83%)
Average
$46.67 (+92.77%)
Lowest
$28.00 (+15.65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alexander Xenakis
Truist Financial
Buy
Reiterated
$49.00
+102.4%
11/06/2026
David Amsellem
Piper Sandler
Hold
Reiterated
$28.00
+15.7%
11/06/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$60.00
+147.8%
11/06/2026
Jenna Davidner
Barclays
Buy
Maintained
$48.00
+98.3%
10/15/2026
Les Sulewski
Oppenheimer
Buy
Reiterated
$50.00
+106.5%
10/09/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
$50.00
+106.5%
09/23/2026
Daniel Clark
Leerink Partners
Buy
Initiated
$45.00
+85.9%
09/09/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
$49.00
+102.4%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
$46.00
+90%
08/06/2026
Unknown Analyst
Jefferies
Buy
Maintained
$51.00
+110.7%
03/20/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$1.96 / $1.86
+5.56%beat
Revenue / Est. (USD)
216.34M / 216.03M
+0.14%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
209.36M
205.45M
193.52M
199.88M
Cost of goods sold
21.66M
21.60M
20.80M
21.22M
Cost of revenue
21.66M
21.60M
20.80M
21.22M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
65.55M
66.67M
86.35M
104.41M
Operating expense
121.02M
122.14M
141.82M
167.36M
Total operating expenses
142.68M
143.74M
162.62M
188.58M
Operating income
66.68M
61.71M
30.90M
11.30M
Other non operating income
-
-
-
-
EBT including unusual items
43.44M
29.04M
18.74M
-13.53M
EBT excluding unusual items
48.03M
45.98M
18.74M
-5.93M
Income tax expense
11.93M
12.07M
4.24M
1.52M
Effective tax rate
27.46%
41.58%
22.65%
-11.23%
Other operating expenses
-
-
-
-
Net income
31.51M
16.96M
14.50M
-15.05M
Net profit margin
15.05%
8.26%
7.49%
-7.53%
Earnings per share
2.25
2.04
1.76
1.92
Interest and investment income
3.12M
3.56M
3.71M
2.29M
Interest expense
-21.77M
-19.29M
-15.86M
-19.52M
Net interest expenses
-18.65M
-15.73M
-12.16M
-17.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
123.18M
118.11M
86.83M
76.06M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps